CELC

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for cancer patients, headquartered in Minneapolis, Minnesota. The company's lead product candidate, gedatolisib, is a dual PI3K/mTOR inhibitor being evaluated in combination with other agents for the treatment of advanced breast cancer and other solid tumors. Celcuity utilizes its proprietary CELsignia diagnostic platform to identify cancer patients most likely to benefit from specific targeted therapies based on cellular signaling pathway analysis. The company is conducting clinical trials to evaluate gedatolisib in patients with HR-positive, HER2-negative metastatic breast cancer. Celcuity aims to improve patient outcomes by matching targeted therapies to patients whose tumors exhibit specific molecular characteristics.